Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Auditor change
|
KalVista Pharmaceuticals, Inc. (KALV)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
12/30/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
02/10/2022 |
SC 13D/A
| Longwood Fund II, L.P. reports a 0% stake in KalVista Pharmaceuticals, Inc. |
01/31/2022 |
SC 13D/A
| Frazier Life Sciences Public Fund, L.P. reports a 6.4% stake in KALVISTA PHARMACEUTICALS, INC. |
02/16/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
04/24/2019 |
SC 13D/A
| RA CAPITAL MANAGEMENT, LLC reports a 4.6% stake in Kalvista Pharmaceuticals, Inc. |
04/15/2019 |
SC 13D/A
| RA CAPITAL MANAGEMENT, LLC reports a 5.6% stake in Kalvista Pharmaceuticals, Inc. |
04/03/2019 |
SC 13D/A
| SVLSF IV, LLC reports a 10.3% stake in KALVISTA PHARMACEUTICALS, INC. |
03/20/2019 |
SC 13D/A
| SVLSF IV, LLC reports a 11.5% stake in KALVISTA PHARMACEUTICALS, INC. |
02/26/2019 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
11/13/2017 |
SC 13D/A
| RA CAPITAL MANAGEMENT, LLC reports a 14.8% stake in Kalvista Pharmaceuticals, Inc. |
10/13/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
09/22/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
03/02/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership [Amend] |
02/13/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership [Amend] |
06/24/2016 |
SC 13D/A
| Carbylan Therapeutics, Inc. reports a 16.5% stake in Carbylan Therapeutics, Inc. |
06/23/2016 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership [Amend] |
|
|